An interventional study of iCAST™ Rx Stent System in Renal Artery Stenosis and Hypertension, Renovascular, sponsored by Atrium Medical Corporation. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-20.
Sponsored by Atrium Medical Corporation · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Renal Artery Obstruction with a site in United States — none open to participants now, none under way, none of them phase 3. Renal Artery Obstruction · United States.
Among the 16 studies in Renal Artery Obstruction with a site in United States, this one is the 7th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2012, is one of 3 with no phase, and was the 12th registered.
59 studies on the registry are indexed under Renal Artery Obstruction; 10 are open to participants now.
Browse Renal Artery Obstruction studies →None of the 16 studies in Renal Artery Obstruction with a site in United States is open now. The open studies under Renal Artery Obstruction, anywhere →
Of the 7 Renal Artery Obstruction studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 3 · Phase 3 4 · Phase 4 1
First in 1992; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is below the median of 100 across 42 interventional studies indexed under Renal Artery Obstruction.
Median enrollment 64 across the 14 interventional studies, 75 across the 1 observational. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 16 have an industry lead sponsor. The 10 most frequent:
Atrium Medical Corporation is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Atrium Medical Corporation has 1 study filed under Renal Artery Obstruction — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Renal Artery Obstruction with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to test how well the iCAST™ RX Stent works in patients diagnosed with atherosclerotic renal artery stenosis and whether or not increased blood flow by the stent will help to control blood pressure.
This is a prospective, single-arm, multicenter clinical trial that will take place at up to 25 US/ Outside US (OUS) sites. Primary endpoints have been determined to show the safety, effectiveness, and clinical outcomes of the iCAST™ RX Stent System. Safety and effectiveness will be evaluated based on the primary patency rate at 9-months on a per lesion basis evaluated against a performance goal of published studies with bare-metal stents. The primary clinical endpoint will assess the improvement in Systolic Blood Pressure (SBP) at 9-months as compared to baseline Systolic Blood Pressure.
Eligible subjects will undergo a two-week Medical Documentation Screening period to confirm resistant hypertension (SBP ≥ 155mmHg) while on maximum tolerable doses of ≥ three anti-hypertensive medications from at least three distinct classes of drugs, one of which must be a diuretic.
There must be documented clinical evidence to support likelihood of angiographic findings > 80% whether it is Duplex Ultrasound (DUS), Computed Tomography angiogram (CTa), Magnetic Resonance angiogram (MRa) or other medical evidence. After meeting screening and clinical eligibility criteria, subjects will undergo a baseline assessment for angiographic eligibility. After angiographic documentation of a ≥ 80% renal artery stenosis or Fraction Flow Reserve (FFR) \< 0.8 is confirmed, the subject may be enrolled in the trial by placement of the investigational device.
The 9-month visit will include a follow-up DUS of the target renal artery. If the DUS is non-diagnostic due to an imaging problem, such as overlying bowel gas or body habitus, a second DUS may be attempted. If the DUS is indicative of ≥ 60% stenosis as determined by the core laboratory, or the second DUS remains non-diagnostic, a contrast angiogram will be used to assess the degree of restenosis of the covered stent(s).
Clinical follow-up visits will be required for all enrolled subjects at 30-days, 9-months, 12-months, 24-months, and 36-months. A 6-month and 18-month visit will occur via telephone to collect medication usage and Adverse Events (AEs) only. The 36-month clinic office visit will be required as the final safety visit.
General Inclusion Criteria:
Subject has a history of maximum tolerable dose of ≥ 3 anti-hypertensive medications of different classes, one of which must be a diuretic (for at least two weeks prior to Medical Documentation Screening period).
a. A documented history for a minimum of 3 months showing reasonable and aggressive efforts to manage hypertension prior to consent. This must include the use of a broad variety of medications that have been used and failed or not tolerated.
Note: When a subject has bilateral Renal Artery Stenosis both of which require stenting, it is recommended to treat both kidneys with an iCAST™ RX Stent System during the index procedure. In the event that a subject needs a renal stenting procedure staged for renal protection, it is important that the Investigator treats the second renal artery with an iCAST™ RX Stent System after 30 days of the index procedure. If subjects with bilateral stenosis have only one lesion that meets protocol inclusion criteria that lesion should be treated per protocol. The recommendation is to NOT treat the second non-qualifying lesion, however if the operator feels strongly it is indicated, then they should treat per standard of care after 30-days post index procedure in order to comply with exclusion criteria #10.
Subjects with flash pulmonary edema are allowed into the trial should they meet all other Inclusion and Exclusion criteria.
Angiographic Anatomic Inclusion Criteria:
Angiographic diameter renal artery stenosis ≥ 80% involving unilateral or bilateral renal arteries.
a. The degree of percent diameter stenosis for all lesions intended to be treated, must be confirmed via one of the following methods: i. Manual or automated measurement with calipers ii. Measured Flow Fraction Reserve (FFR) \< 0.8 using a pressure wire iii. Measured translesional peak pressure gradient of > 21 mmHg after induced hyperemia via dopamine or papaverine using a 4 Fr or less catheter or pressure wire.
b. Subjects with 60-79% angiographic stenosis who have confirmed FFR \< 0.8 may be enrolled.
General Exclusion Criteria:
Angiographic Anatomic Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All enrolled subjects will receive the iCAST RX™ Stent System
Device: iCAST™ Rx Stent System
All enrolled subjects will undergo primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.
Also known as: iCAST™ RX
Primary Patency
Primary patency rate at 9 months was defined as continuous patency without the occurrence of a total occlusion of the original lesion, without a re-intervention to treat a partial or total occlusion of the stented segment, or bypass of the stented segment due to clinically-driven restenosis or occlusion.
Time frame: 9 months
Systolic Blood Pressure
Change in systolic blood pressure (SBP) at 9 months as compared to baseline SBP.
Time frame: Baseline and 9 months
Procedure-Related Major Adverse Events (MAE)
The occurence of procedure-related MAEs is reported as a percentage of subjects with MAE. Inclusive of: 1. Procedure- or device-related occurrence of death 2. Q-Wave myocardial infarction (MI) 3. Clinically driven target lesion revascularization (TLR) 4. Significant embolic events defined as unanticipated kidney/bowel infarct, clinically driven by symptoms of abdominal or back pain and confirmed with CT scan or open surgery; lower extremity ulceration or gangrene; or kidney failure.
Time frame: 30 days, 9 months
Technical Success
Technical success is defined as successful delivery and deployment of the iCAST™ RX Stent System with ≤ 30% residual angiographic stenosis after covered stent deployment (including post-dilatation) assessed via quantitative vascular analysis (QVA) by an independent core laboratory.
Time frame: Day of Procedure
Acute Procedural Success
Acute procedural success is defined as technical success without the occurrence of MAE prior to hospital discharge.
Time frame: Day of Procedure, prior to hospital discharge
Target Lesion Revascularization (TLR)
Target Lesion Revascularization (TLR) is measured as the proportion of subjects-lesions that require a clinically-driven reintervention of the target lesion through 9 months. a. A clinically-driven TLR is defined as a TLR (percutaneous balloon angioplasty (PTA), bare metal stent or repeat covered stent deployment, or surgical bypass) due to documented recurrent hypertension from 30-days post-procedure level and/or deterioration in renal function from baseline value, associated with angiographic core laboratory adjudication of a ≥ 60% diameter covered stent restenosis.
Time frame: 9 months
Rate of Incidental TLR
The rate of incidental TLR is the rate of TLRs not meeting the definition of a clinically-driven TLR.
Time frame: 9 months
Systolic Blood Pressure (SBP) Control
The change in SBP from baseline to 30 days
Time frame: Baseline and 30 days
SBP Control
The change in SBP from baseline to 9 months
Time frame: Baseline and 9 months
Secondary Patency Rate
Secondary patency rate at 9 months after a clinically-driven TLR which restores patency after total occlusion.
Time frame: 9 months
Change in Number of Anti-Hypertensive Medications
Change in number of anti-hypertensive medications as compared to baseline.
Time frame: Baseline and 9 months
Change in Renal Function
Renal function compared to baseline as measured by estimated Glomerular Filtration Rate (eGFR) at 30 days.
Time frame: Baseline and 30 days
Change in Renal Function
Renal function compared to baseline as measured by estimated Glomerular Filtration Rate (eGFR) at 9 months.
Time frame: Baseline and 9 months
| Milestone | iCAST™ RX Stent System |
|---|---|
| Started | 68 |
| Completed | 66 |
| Not completed | 2 |
| Withdrew: Death | 2 |
Primary patency rate at 9 months was defined as continuous patency without the occurrence of a total occlusion of the original lesion, without a re-intervention to treat a partial or total occlusion of the stented segment, or bypass of the stented segment due to clinically-driven restenosis or occlusion.
| Subject-lesions | iCAST™ RX Stent System |
|---|---|
| Primary Patency | 66 |
Change in systolic blood pressure (SBP) at 9 months as compared to baseline SBP.
| mmHg | iCAST™ RX Stent System |
|---|---|
| Systolic Blood Pressure | 15.7 ± 21.20 |
The occurence of procedure-related MAEs is reported as a percentage of subjects with MAE. Inclusive of: 1. Procedure- or device-related occurrence of death 2. Q-Wave myocardial infarction (MI) 3. Clinically driven target lesion revascularization (TLR) 4. Significant embolic events defined as unanticipated kidney/bowel infarct, clinically driven by symptoms of abdominal or back pain and confirmed with CT scan or open surgery; lower extremity ulceration or gangrene; or kidney failure.
| Participants | iCAST™ RX Stent System |
|---|---|
| Overall subjects experiencing MAE | 5 |
| MAE within 30 days | 0 |
| MAE within 9 months | 2 |
Technical success is defined as successful delivery and deployment of the iCAST™ RX Stent System with ≤ 30% residual angiographic stenosis after covered stent deployment (including post-dilatation) assessed via quantitative vascular analysis (QVA) by an independent core laboratory.
| Subject-lesions | iCAST™ RX Stent System |
|---|---|
| Technical Success | 81 |
Acute procedural success is defined as technical success without the occurrence of MAE prior to hospital discharge.
| Subject-lesions | iCAST™ RX Stent System |
|---|---|
| Acute Procedural Success | 81 |
Target Lesion Revascularization (TLR) is measured as the proportion of subjects-lesions that require a clinically-driven reintervention of the target lesion through 9 months. a. A clinically-driven TLR is defined as a TLR (percutaneous balloon angioplasty (PTA), bare metal stent or repeat covered stent deployment, or surgical bypass) due to documented recurrent hypertension from 30-days post-procedure level and/or deterioration in renal function from baseline value, associated with angiographic core laboratory adjudication of a ≥ 60% diameter covered stent restenosis.
| Subject-lesions | iCAST™ RX Stent System |
|---|---|
| Target Lesion Revascularization (TLR) | 3 |
The rate of incidental TLR is the rate of TLRs not meeting the definition of a clinically-driven TLR.
| Subject-lesions | iCAST™ RX Stent System |
|---|---|
| Rate of Incidental TLR | 2 |
The change in SBP from baseline to 30 days
| mmHg | iCAST™ RX Stent System |
|---|---|
| Systolic Blood Pressure (SBP) Control | -13.6 ± 18.83 |
The change in SBP from baseline to 9 months
| mmHg | iCAST™ RX Stent System |
|---|---|
| SBP Control | -15.7 ± 21.20 |
Secondary patency rate at 9 months after a clinically-driven TLR which restores patency after total occlusion.
| Subject-lesions | iCAST™ RX Stent System |
|---|---|
| Secondary Patency Rate | 3 |
Change in number of anti-hypertensive medications as compared to baseline.
| Number of Anti-hypertensive Medications | iCAST™ RX Stent System |
|---|---|
| Change in Number of Anti-Hypertensive Medications | -0.1 ± 0.76 |
Renal function compared to baseline as measured by estimated Glomerular Filtration Rate (eGFR) at 30 days.
| eGFR mL/min/1.73 m^2 | iCAST™ RX Stent System |
|---|---|
| Change in Renal Function | -0.5520 ± 8.42795 |
Renal function compared to baseline as measured by estimated Glomerular Filtration Rate (eGFR) at 9 months.
| eGFR mL/min/1.73 m^2 | iCAST™ RX Stent System |
|---|---|
| Change in Renal Function | -1.9964 ± 13.42781 |
Collected over Non-serious Adverse Events were reported through 9 months. Serious Adverse Events were reported through 3 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| iCAST™ RX Stent System | 4/68 (5.9%) | 40/68 (58.8%) | 12/68 (17.6%) |
| Event | iCAST™ RX Stent System |
|---|---|
| Arterial restenosisInjury, poisoning and procedural complications | 8/68 |
| Angina pectorisCardiac disorders | 7/68 |
| Cardiac failure congestiveCardiac disorders | 6/68 |
| PneumoniaInfections and infestations | 6/68 |
| ArrhythmiaCardiac disorders | 5/68 |
| Cerebrovascular accidentNervous system disorders | 4/68 |
| AnaemiaBlood and lymphatic system disorders | 3/68 |
| Myocardial infarctionCardiac disorders | 2/68 |
| Urinary tract infectionInfections and infestations | 2/68 |
| Renal failure acuteRenal and urinary disorders | 2/68 |
| Event | iCAST™ RX Stent System |
|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/68 |
| AnaemiaBlood and lymphatic system disorders | 4/68 |
| Subcutaneous haematomaInjury, poisoning and procedural complications | 4/68 |
| Age, Categorical(Participants) | iCAST™ RX Stent System |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 16 |
| >=65 years | 52 |
| Age, Continuous(years) | iCAST™ RX Stent System |
|---|---|
| Mean | 71.7 ± 10.17 |
| Sex: Female, Male(Participants) | iCAST™ RX Stent System |
|---|---|
| Female | 35 |
| Male | 33 |
| Ethnicity (NIH/OMB)(Participants) | iCAST™ RX Stent System |
|---|---|
| Hispanic or Latino | 6 |
| Not Hispanic or Latino | 62 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | iCAST™ RX Stent System |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 7 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 4 |
| White | 53 |
| More than one race | 3 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | iCAST™ RX Stent System |
|---|---|
| United States | 68 |
| Number of Qualifying Lesions(Participants) | iCAST™ RX Stent System |
|---|---|
| Unilateral | 54 |
| Bilateral | 14 |
| Systolic Blood Pressure(mmHg) | iCAST™ RX Stent System |
|---|---|
| Mean | 166.2 ± 12.19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2012 to primary completion in Jun 2018, 68 months.
Results were first posted in Aug 2019, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Atrium Medical Corporation